CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
CNS Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.99+0.14 (+2.87%)
Close on Oct 19, 2026
- Market cap
- $34.12M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.21 (−45.76%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $34.12M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.87
- Dividend yield
- –
- Free cash flow yield
- -40.53%
Fundamentals
- Net income
- -$16.70M
- EPS, diluted
- -$23.14
- Free cash flow
- -$13.83M
- Book value per share
- $2.66
- Diluted shares
- 7M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
-$16.91M
Net income
-$16.70M
EPS, diluted
-$23.14
Free cash flow
–
Reported periodTrailing twelve months